Key points are not available for this paper at this time.
Abstract Background The Oncotype DX Breast Recurrence Score assay (ODX) is a commonly used genomic test for patients with estrogen receptor (ER)-positive, HER2-negative, early-stage invasive breast cancer. While ODX predicts patients’ recurrence risk and benefit from chemotherapy, it is tissue and time-consuming, and expensive. Previous deep-learning or non-linear ODX prediction models achieved promising performance using whole-slide images (WSI) or with other covariates (e.g., ER, progesterone receptor (PR), HER-2, Ki-67 scores and tumor stage) but systematic quantification of the contribution of individual histological features to the ODX score remained challenging. Here, we extracted a rich set of human-interpretable features (HIFs) quantifying nuclear morphology and the distribution of cells and tissues in the tumor microenvironment. We used these HIFs, along with manually assessed ER, PR, HER-2 scores, and tumor stage, to predict ODX scores. We also explored the role of Ki-67 features in augmenting our model predictions Methods We developed machine learning models to extract cell, tissue, and nuclear HIFs from WSI stained with hematoxylin and eosin (H 10-7), macrophage density (p 10-4), immune cell density (p 10-16), and variations in cancer nuclear size (p 10-5) and color (p 10-3). Significant negative correlations were observed between ODX scores and clusters related to fibroblast density (p 10-3), and variations of non-cancer cell nuclear color (p = 0.02). Evaluation of our model’s ability to predict ODX scores revealed an association between predicted and observed scores (Pearson r = 0.74). The AUROC for model predictions of high/low classifications (with reference to a cutoff ODX score of 20) was 0.80. Ki-67 features were clustered together with H 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-07-01.
Building similarity graph...
Analyzing shared references across papers
Loading...
Nhat Le
John Van Arnam
Christian Kirkup
Cancer Research
Cleveland Clinic
Critical Path Institute
SignPath Pharma (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Le et al. (Thu,) studied this question.
www.synapsesocial.com/papers/68e6be94b6db64358763e72c — DOI: https://doi.org/10.1158/1538-7445.sabcs23-po1-07-01